TG Therapeutics to Present at Upcoming Investor Conferences
September 09 2020 - 9:17AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its
participation at two upcoming virtual investor conferences. Michael
S. Weiss, the Company’s Executive Chairman and Chief Executive
Officer, is scheduled to participate in fireside chats during the
following conferences:
- The H.C. Wainwright 22nd Annual Global Investment Conference –
fireside chat scheduled to take place on Monday, September 14, 2020
at 1:30 PM ET
- The Cantor Fitzgerald Global Healthcare Conference – fireside
chat scheduled to take place on Wednesday, September 16, 2020 at
10:40 AM ET
A live webcast of each presentation will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell malignancies and autoimmune diseases.
Currently, the company is in late stage clinical development with
two investigational compounds, ublituximab and umbralisib, the
combination of which is referred to as “U2”, targeting
hematological malignancies and autoimmune diseases. Ublituximab
(TG-1101) is a glycoengineered monoclonal antibody that targets a
specific and unique epitope on the CD20 antigen found on mature
B-lymphocytes. Umbralisib (TGR-1202) is an oral, once-daily
dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib is
currently under review by the U.S. Food and Drug
Administration (FDA) for accelerated approval as a treatment
for patients with previously treated marginal zone lymphoma
(MZL) who have received at least one prior anti-CD20
based regimen or follicular lymphoma (FL) who have
received at least two prior systemic therapies. The Company also
has a fully enrolled Phase 3 clinical trial evaluating U2 in
patients with treatment naïve and relapsed/refractory chronic
lymphocytic leukemia (CLL), and two fully enrolled identical Phase
3 trials evaluating ublituximab monotherapy in patients with
relapsing forms of multiple sclerosis (RMS). Additionally, the
Company has recently brought into Phase 1 clinical development its
anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its
covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701,
as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG
Therapeutics is headquartered in New York City.
CONTACT:
Jenna BoscoSenior Vice President,Corporate CommunicationsTG
Therapeutics, Inc.Telephone:
212.554.4351Email: ir@tgtxinc.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024